ALTTO

FSS is collaborating with the Breast International Group (BIG) and GlaxoSmithKline on the ALTTO and neo-ALTTO trials. These trials follow on from the successful HERA trial and compare Herceptin® with a new drug Lapatinib, both as single agents and in combination. FSS is responsible for randomisation, various aspects of project managment, data quality control and for statistical programming and analysis. This trial involves participation of breast cancer trials groups and independent sites around the world, including North America. The North American participation in the trial is co-ordinated by the North Central Cancer Treatment Group (NCCTG). much of the translational work in neo-ALTTO is co-ordinated by the Spanish Group, SOLTI.